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Abstract
Enzymes are critically important in the transportation, metabolism, and clearance of
most therapeutic drugs used in clinical practice today. Many of these enzymes have
significant genetic polymorphisms that affect the enzyme’s rate kinetics. Regarding
drug metabolism, specific polymorphisms to the cytochrome (CYP) P450 enzyme
family are linked to phenotypes that describe reaction rates as “ultra”, “intermediate”,
and “poor,” as referenced to “extensive” metabolizers that are assigned to wildtype
individuals. Activity scores is an alternate designation that provides more genotype-
to-phenotype resolution. Understanding the relative change in enzyme activities or
rate of clearance of specific drugs relative to an individual’s genotypes is an
important component in the interpretation of pharmacogenomic data for
personalized medicine. Currently, the most relevant drug metabolizing enzymes are
CYP 2D6, CYP 2C9, CYP 2C19, thiopurine methyltransferase (TPMT) and UDP-
glucuronosyltransferase (UGT). Each of these enzymes is reactive to a host of
different drug substrates. Pharmacogenomic tests that are in routine clinical practice
include CYP 2C19 for clopidogrel, TPMT for thiopurine drugs, and UDP-1A1 for
irinotecan. Other tests where there is considerable data but have not been widely
implemented includes CYP 2C9 for warfarin, CYP 2D6 for tamoxifen and codeine, and
CYP 2C19 for the proton pump inhibitors.
1. Introduction
Pharmacogenomics is an important tool for the personalization of medical therapeu-
tics. The determination of an individual’s genotype for key enzymes that participate in
the transportation, metabolism, and clearance is a strong determinant of therapeutic
efficacy and toxicity avoidance. Regarding drug metabolism, subjects who have no or
slower rate of enzyme activity than normal have higher circulation drug concentrations
and are vulnerable to toxicity when the standard dosage is used. Individuals who have
a faster of enzyme activity have lower circulating drug concentrations and may be sub-
therapeutic at standard dosage. The situation is reversed for medications (prodrugs)
that require enzymatic activation; poor metabolizers are unable to produce substantial
quantities of bioactive drugs and rapid metabolizers produce too much. The optimum
use of therapeutic drugs requires some knowledge of enzyme catabolic rates and how
it affects the activation, inactivation, or clearance. The relationship between enzyme
activity and pharmacogenomics has been extensively reviewed, e.g., the reader is
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Academy of Clinical Biochemistry (NACB) [1].
2. Phenotype assessments and genotype classification schemes
In a living person, it is difficult if not impossible to determine the phenotype of an
individual for a specific hepatic enzyme due to the inability to obtain liver tissue. With
the exception of thiopurine methyltransferase, the analysis of activity from blood is not
a surrogate of tissue enzyme activity, as it is only a reflection of tissue necrosis and
turnover. Measurement of the rate of substrate metabolism and/or product formation
is therefore used to the assess phenotypes. This requires the subject to have taken the
drug, either in single dosage or at steady state. Accurate assessments also require that
the subject be free of other influences such as co-medications that can induce or inhi-
bit hepatic gene expression or enzyme activity. The analysis of the genetic makeup for
metabolic genes is an alternate means to assess rates of metabolic capability. Analysis
for germ-line polymorphisms has the advantage of not needing the individual to be on
the drug itself. There have been schemes developed to correlate genotypes to pheno-
types which are relevant for clinical pharmacogenomics.
The classical phenotype classification scheme for a specific drug is to compare indivi-
duals with variant activities against those who were considered normal or comprised of
the majority of subjects, and are defined as the wildtype “extensive metabolizer.” As
shown in Table 1 among the variant genotypes are poor metabolizers (PM) associated
with the presence of null genotypes, intermediate metabolizers (IM) with reduced
metabolism genotypes, and ultra-rapid metabolizers (UM) as having gene duplications.
This classical designation of metabolic states is rather simplified and does not explain
all of the possible combinations of two variant alleles. Therefore the activity score was
created which assigns for each allele, a value of 0 for null, 0.5 for intermediate, 1.0 for
wildtype and 2 times these scores for the corresponding gene duplication genotypes
[2]. This scoring scheme enables the classification of two additional intermediate states
between PM and IM, and IM and EM (Table 1). Within this framework, the remainder
of this review focuses on enzymatic rates for specific substrates that have current or
near future relevance in clinical practices. Phenotype-genotype analyses for other
enzyme-catalyzed metabolic pathways have been described, e.g., glutathione-S-transfer-
ase and the remethylation pathways, are herein not discussed.
Table 1 Association of enzyme metabolic rates to genotypes
Classical metabolism status Activity score
1 Genotypes
Poor metabolizer (PM) 0.0 Homozygous null gene
0.5 Heterozygous null and reduced metabolism
Intermediate metabolizer (IM) 1.0 Homozygous reduced metabolism
Heterozygous null and wildtype
1.5 Heterozygous reduced metabolism and wildtype
Extensive metabolizer (EM) 2.0 Homozygous wildtype
Heterozygous null and ultra metabolism
Heterozygous reduced and ultra metabolism
Ultra-rapid metabolizer (UM) > 2.0 Heterozygous wildtype and ultra metabolism
Homozyogous ultra metabolism
1For each allele, a score of 0 is given for null genes, 0.5 for intermediate, and1.0 for extensive metabolizers. Alleles
carrying gene duplications receive double the value compared to the assigned activity score with a single gene copy.
The sum of both alleles is given.
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The cytochrome enzymes currently consist of 57 enzymes containing different family
and subfamily members and isoenzymes within each of them [1]. The most clinically
relevant isoforms for pharmacogenomic practice are CYP 2D6, CYP 2C9, and CYP
2C19. Each of the major isoenzymes have genetic variants that may or may not affect
catabolic rates. For many genes, there are a large number of variants. It is not practical
or necessary to phenotypically characterize each variant, and only polymorphisms with
the highest incidence and where data is available will be discussed.
CYP 2D6
CYP 2D6 is also known as debrisoquine hydroxylase that catalyzes the oxidation of
approximately a quarter of all the commonly therapeutic drugs in used clinical practice
today. CYP 2D6 hydroxylates aromatic rings or an accompanying short side-chain of
basic aryl-alkyl amines containing a protonated nitrogen. Of all enzymes of pharmaco-
kinetic importance, the CYP 2D6 gene that encodes this enzyme has one of the highest
numbers of genetic polymorphisms, with over 100 variants described to date [3]. How-
ever, many of these variants are rare and are not detected by routine CYP 2D6 single
nucleotide polymorphism (SNP) assays. These variants can only be verified by sequen-
cing of the CYP 2D6 gene. Studies indirectly characterizing the enzymatic activity of
CYP 2D6 variants have used model drugs known to be effective substrates. In the
model developed by Gaedigk et al., the ratio of dextromethorphan (DM) and its princi-
pal metabolite o-demethylated metabolite (DX) in a 4-hour urine collection was used
following a single 0.3 mg/kg dose [4]. Using the DM/DX ratio, these investigators gen-
eralized that the PM was ≥0.3, IM between 0.03 and 0.3, EM between 0.03 and 0.0003,
and UM < 0.0003. This indicates that relative to the wildtype, PM subjects had
between 100 and 1000 times less enzyme activity, the IM subjects had between 10 and
100 times less activity, and UM had greater (sometimes 10 fold higher) enzyme activ-
ity. It should be noted that within a classification, there were significant overlap in the
DM/DX ratio. While drugs are used to control specific and easily quantifiable symp-
toms, e.g., dextromethorphan is widely used as an antitussive, there may be no interest
in performing routine clinical pharmacogenomic testing. Dosing and efficacy can be
assess clinically, e.g., by the presence or absence of coughing.
In contrast, an analysis of CYP 2D6 polymorphism is important in the assessment of
patients with breast cancer treated with the prodrug tamoxifen, a selective estrogen
receptor modulator. Tamoxifen is activated through two pathways to the final product,
endoxifen, which is the 10-100 fold more effective in blocking estrogen receptors than
tamoxifen itself. The major pathway is first to N-desmethyltamoxifen (NDM) through
CYP3A and then endoxifen via CYP 2D6. The minor pathway is to 4-hydroxytamoxi-
fen through CYP 2D6, CYP 2B6, CYP 2C9, and CYP 2C19, and then to endoxifen
through CYP 3A. In a study by Borges et al., the ratio of endoxifen to NDM was deter-
m i n e di nag r o u po fp a t i e n t sw h ow e r eP M ,I M ,a n dE M[ 5 ] .T h er e l a t i v ee n z y m e
activity for the EM was roughly double that of the IM (0.15 vs. 0.08, respectively),
which in turn was double that of the PM (0.08 vs. 0.04). The effect of genetic poly-
morphism for tamoxifen metabolism is considerably less than for dextromethorphan,
due to the existence of alternate non-CYP 2D6-dependent metabolic pathways. Given
that there is a minimum amount of endoxifen needed for therapeutic efficacy
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effectively block estrogen receptors, and other medications such as aromatase inhibi-
tors are preferred [7]. The importance of CYP 2D6 genotypes for tamoxifen therapy
for disease and relapse-free survival for breast cancer patients continues to be debated
with studies showing both benefits [8] and no benefit [9].
The pharmacogenomics of the tricyclic antidepressants has been examined. The
major metabolic pathway for amitriptyline is demethylation to the active metabolite
nortriptyline by CYP 2C19. Thereafter, nortriptyline is deactivated by hydroxylation to
10-hydroxy metabolite by CYP 2D6. Steimer et al. compared the relative change in
serum nortriptyline concentrations following 75 mg twice a day, as a function of var-
iant CYP 2D6 alleles (*2,* 4,* 10,a n d* 41) against the wildtype (*1)[ 1 0 ] .T h e yf o u n d
no significant difference in nortriptyline concentrations for *2 (thereafter the *1 and *2
groups were combined), a 40% (1.9-fold) decreased enzyme activity for *41,6 3 %( 2 . 7 -
fold) decrease for *10, and a 96% (3.8-fold) decrease for *4. For combinations of variant
alleles, the expected effect would be multiplicative, e.g., the *4/*41 genotype would
have 173% reduced enzyme activities. Previously, the *10 and *41 alleles were asso-
ciated with intermediate metabolism and the *4 allele was associated as a poor metabo-
lizer [11]. These results are consistent with these classifications. The toxicities of
tricyclic antidepressants are well described and develop gradually. Therefore, most psy-
chiatric practices have not endorsed routine CYP 2D6 testing of their patients.
The enzyme reaction rate for the metabolism of codeine to morphine by o-demethy-
lation by CYP 2D6 has been studied. Kirchheiner et al. examined the ratio of plasma
area under the curve for morphine vs. codeine in relation to CYP 2D6 activity score
[12]. They found that the extensive metabolizers (activity score 1.5 and 2.0) was 6 and
16-fold more active than the poor metabolizer (score 0.0), while the ultra metabolizer
(3 full activity copies, score 3.0) had 50% more activity than the extensive metabolizers.
Clinical pharmacogenomic testing is relevant for opiates, as morphine toxicity has been
described in patients who are ultra-metabolizers of codeine [13]. Recently the FDA has
issued a warning to physicians and consumers to be on the alert for unexpected signs
and symptoms of morphine toxicity for patients with therapeutic dosing of codeine
use. Nevertheless, the development of morphine toxicity is based on clinical presenta-
tion and routine screening for CYP 2D6 is impractical and expensive to the overall
healthcare system, given the large number of subjects on opiate drugs.
CYP 2C19
CYP 2C19 is also known as S-mephenytoin hydroxylase. CYP 2C19 acts on weakly or
strongly basic drugs containing one hydrogen bond donor or if there are functional
groups containing carbon or sulfur double bonded to oxygen present in the substrate.
CYP 2C19 is responsible for the metabolism of anticonvulsant drugs, proton pump
inhibitors, and drugs that inhibit platelet function. There have been no gene duplica-
tions described for the gene for this enzyme.
CYP 2C19 is a key enzyme in the activation of the clopidogrel, a widely used anti-
platelet agent. Clopidogrel is metabolized first to 2-oxoclopidogrel and then to R-
130964, the active metabolite that binds to the P2Y12 platelet receptor. There have
been numerous reports demonstrating that individuals who are carriers for one or
more of the poor function alleles for CYP 2C19, i.e., *2 or *3, have a higher incidence
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need for urgent revascularization [14,15]. The relative rate of metabolism for UM
(CYP 2C19 *17), EM (*1/*1), IM (*1/*2 or *1/*3), and PM (*2/*2, *2/*3, or *3/*3) have
been reported by Mega et al., who developed a na s s a yf o rt h ea c t i v em e t a b o l i t e[ 1 5 ] .
Using a 75 mg maintenance dose, individuals who had one copy of a null gene (IM)
had a 30.7% lower area under the drug vs. time curve (AUC) vs. the wildtype, and
those with two copies (PM) had a 45.6% lower AUC vs. the wildtype. The pharmaco-
dynamic of a reduced metabolism genotype for clopidogrel is a decrease in the degree
of platelet inhibition as measured by aggregation. This suggest therapeutic benefit with
use of a higher dose, although there have been no published study to date that has
documented the efficacy of increased dosing. Another option is to use an alternate pla-
telet-inhibiting drug such as prasugrel, another prodrug but whose pharmacologic
activity is not influenced by CYP 2C19 polymorphism [16].
The proton pump inhibitors (PPIs) are a class of compounds including omeprazole,
lansoprazole, rabeprazole, esomeprazole, and pantoprazole, and are used to selectively
and irreversibly inhibit gastric acid secretion. They have become essential in the treat-
ment of patients with peptic ulcers, gastroesophageal reflux diseases and Zollinger-Elli-
son syndrome. They are also used for the eradication of Helicobacter pylori in
combination with antibiotics. The PPIs metabolism by CYP 2C19. Relative to the wild-
type, patients who are poor and intermediate metabolizers have an area under the
omeprazole plasma concentration curve that is 6.8 and 3.0 times higher, respectively
following 20 mg dosages [17]. Similar results are observed for rabeprazole at 5.3 and
1.7 times higher, respectively for these genotypes at 20 mg doses. The pharmacody-
namic effect of the accumulation of PPIs due to reduced metabolism genotypes is a
reduction in acid secretion, at least for omeprazole. Less drug is needed for therapeutic
effectiveness among poor metabolizer patients. If through clinical trials pharmacoge-
nomic testing can reduce the incidence of bleeding, testing routine testing for initial
dosing will be justified.
CYP 2C9
CYP 2C9 is another important member of the CYP P450 family responsible for meta-
bolizing over 100 therapeutic drugs. The enzyme oxidizes neutral and acidic amphipa-
tic drugs with a hydrophobic region. One hydrogen bond donor or anionic heteroatom
is required. The relevant genotypes include *2 and *3, which are both associated with
decreased enzyme activity. There are no CYP 2C9 gene duplications or deletions. The
relative rate of enzyme activity has been described using 500 mg of the oral hypoglyce-
mic drug tolbutamine as a model drug. The rate of metabolism to 4’-hydroxy-tolbuta-
mide versus CYP 2C9 genotypes has been examined in healthy volunteers. Compared
to the wildtype, individuals with intermediate metabolism (*1/*2 or *1/*3)h a da7 9 %
and 54% slower rate of metabolism, respectively [18]. Interestingly, the homozygous
poor metabolizer (*2/*2) was only slightly lower at 52%.
While there is no clinical interest in tolbutamide for clinical pharmacogenomics,
there is considerable interest in testing CYP 2C9 polymorphisms for S-warfarin dosing,
especially when used in conjunction with demographic variables (age, gender, body
weight) and genetic variances for vitamin K epoxide reductase complex subunit 1
(VKORC1). There are significance differences in the clearance rates for wildtype
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average of 45% lower clearance rate than the wildtype. The *2/*2 and *2/*3 variants
had a 72% lower clearance rate, while the *3/*3 homozygous patient had an 88% lower
clearance rate for warfarin than the wildtype [19]. The reduced clearance of the drug is
related to the slower rate of enzyme activity for *2 and *3, estimated to be 12% and 5%
of wildtype, for the *2 and *3 alleles, respectively [20]. Similar results have been
reported for other oral anticoagulants. Thijssen et al. showed patients with the *1/*3
genotype had mean oral clearance rate that was 45% lower than the wildtype for ace-
nocoumarol [21], and Ufer et al. reported 51% and 29% reduce clearance rates, respec-
tively, for *2 and *3 for phenprocoumon [22]. For any of these drugs, there was no
effect of CYP 2C19 polymormism on the pharmacokinetics of the less pharmacologi-
cally active R-isomers. Patients with reduce metabolism for CYP 2C9 require lower
dosing than the standard 5 mg/day given to wildtype patients. The -1639 AA genotype
for VKORC1 is also associated with a reduced warfarin dose requirement. The relative
activities of other drug classes metabolized by CYP 2C19 such as nonsteroidal anti-
inflammatory, antidiabetics, anticonvulsants, and angiotensin antagonists have also
been reported [19].
4. Other metabolic enzymes
Thiopurine methyltransferase (TPMT)
Thiopurine methyltransferase catalyzes the S-methylation of aromatic and heterocyclic
sulfhydryl compounds such as mercaptopurine, and azathiopurine. These drugs are
widely used to suppress the immune system for treatment of patients with autoim-
mune disease, leukemias and lymphomas, and following organ transplantation. Unlike
the cytochrome P450 enzymes discussed above, genetic polymorphisms in TPMP are
less frequent (8-10% for individuals heterozygous for *3A and *3C). When present,
however, there are significant toxicological consequences to the affected individual,
particularly related to hematopoietic dysfunction. TMPT is widely expressed including
in erythrocytes in contrast to the cytochrome P450 enzymes which are located within
the hepatocytes. Therefore the phenotype (enzyme activity) can be measured directly.
Patients with the heterozygous intermediate genotype on the average had 1.7 times
lower TPMP activities than the wildtype [23]. More significantly, those who have the
poor metabolizer genotype for TMPT has 29 times lower enzyme activities than the
wildtype and are particularly vulnerable to toxicity. Low activity alleles have been
l i n k e dt oah i g h e rc u r er a t ei nc h i l d h o o dacute lymphocytic leukemia [24] but also a
higher risk of second malignancies [25]. There is debate regarding the efficacy of geno-
typing vs. phenotyping for TPMT variances. Genotyping has an advantage in that it
can be conducted in patients following blood tranfusions and is less technically
demanding than the red blood cell enzymatic assay [26]. Phenotyping has the advan-
tage of detecting rare variants that are not tested for by the targeted genetic assay. Irre-
spective as to which approach is taken, routine screening is warranted for patients on
these medications given the significant and life-threatening consequences of inap-
propriate dosing.
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UDP-glucuronyltransferase is a phase II enzyme that catalyzes the glucuronidation of
various endogenous compounds such as bilirubin and steroids, and exogenous com-
pounds such as drugs. The 1A1 isoenzyme acts on bilirubin and the colon cancer drug
irinotecan, a prodrug that undergoes metabolism to the active metabolite SN-38 and
then is inactivated via glucuronidation to SG-38N. The genetic variance in UDP 1A1 is
characterized by the presence of additional TA repeats in the TATA sequence of the
promoter gene. The wild type consists of 6 copies (*1). While 5 and 8 copies can
occur, a common polymorphism is the presence of 7 TA repeats (*28). The enzymatic
activity of individuals who are heterozyous (*1/*28) and homozygous (*28/*28)a r e2 . 3
and 3.8 fold lower than the wildtype (*1/*1), respectively [27]. Accumulation of the
SN-38 metabolite due to a decrease glucuronidation leads to gastrointestinal and
hematopoietic toxicity. Lower doses of irinotecan and adding other chemotherapeutic
agents such as cis-platin to the regimen would be indicated to treat these cancer
patients to maintain efficacy and reduced side effects. Pharmacogenomic testing is indi-
cated to avoid toxicities if drug doses are reduced in patients with variant genotypes.
Summary
Understanding the relative enzyme activities for each genotype is only the first step in
understanding the role of polymorphisms in the metabolism of relevant drugs. How-
ever, most drugs are metabolized my multiple enzyme pathways. Thus, even if an indi-
vidual produces an inactive variant for an enzyme in the major pathway, the drug can
be broken down through an alternate or minor pathway, assuming that these enzymes
are not affected genetically. It is also likely that the mRNA expression of these genes
from these individuals are up-regulated to compensate for the presence of the deficient
enzyme. Therefore, estimations of reaction rates for a particular enzyme in isolation
will overestimate the collective degree of metabolic activity. On the other hand, some
individuals can simultaneously carry several null or reduced function alleles for multi-
ple CYP genes. These individuals in particular will exhibit significant variances in the
pharmacologic effect of the drugs relevant to their pharmacogenomic makeup.
The debate between the importance of genotyping versus phenotyping will continue
for years to come with the weight of evidence for a particular drug favors one
approach over the other. As these attributes are complementary, it is very likely that a
combination of both will be useful in individualizing therapy for a given patient. For
warfarin, genotying is important for initial dosing to avoid adverse events in initiation
phase, but this does not supercede the need for therapeutic monitoring of anticoagula-
tion. Should pharmacogenomic testing for tamoxifen become routine, identification of
patients who are poor metabolizers may lead to an immediate decision to use an alter-
nate medication. For wildtypes, tamoxifen can be administered to the premenopausal
patient. Once steady state has been reached. therapeutic drug monitoring for endoxifen
concentrations will be best in predicting outcomes given that the use of drug inhibitors
can result in low metabolite levels. For clopidogrel, genotyping only affects the drugs
pharmacokinetics. Testing for platelet function assess the drug’s pharmacodynamic
effect. A combination of genotyping and phenotyping may be important to make a
medical decision of administering an alternate drug or increasing the dosage of clopi-
dogrel itself. Clinical trials are needed to verify the value and economical justification
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